Clicky

Cipher Pharmaceuticals Inc(PHE)

Description: Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome. The company's licensed products comprise Absorica, an oral retinoid indicated for the treatment of f severe nodular and/or inflammatory acne, acne conglobate and recalcitrant acne; Lipofen, which is indicated as adjunctive therapy to diet to reduce elevated LDL-C, total-C, triglycerides, and Apo B, and to increase HDL-C, as well as to reduce triglycerides in adult patients; and Conzip, an opioid agonist indicated for the management of moderate to moderately severe chronic pain in adults. Its pipeline products include MOB-015, a topical formulation of terbinafine, which is in phase 3 clinical trial for treatment of onychomycosis; CF-101 (Piclidenoson) that is in phase 3 clinical trial for severe plaque psoriasis and rheumatoid arthritis; and DTR-001, a tattoo removal cream, which is in pre-clinical stage. Cipher Pharmaceuticals Inc. was founded in 2000 and is headquartered in Mississauga, Canada.


Keywords: Pharmaceutical Pain Rheumatoid Arthritis Acne Acute Coronary Syndrome Onychomycosis Severe Plaque Psoriasis Acneiform Eruptions Adjunctive Therapy Anti Acne Preparations Puberty Isotretinoin Aggrastat Impetigo Topical Solution Actikerall Inflammatory Acne Minocycline Terbinafine Brinavess Cf 101 Durela Epuris Infantile Acne Lipofen Moderately Severe Chronic Pain Moderately Thick Hyperkeratotic Actinic Keratosis Recalcitrant Acne Retinoids Tretinoin Vaniqa

Home Page: www.cipherpharma.com

5750 Explorer Drive
Mississauga, ON L4W 0A9
Canada
Phone: 905 602 5840


Officers

Name Title
Mr. Craig J. Mull Interim CEO & Chairman of the Board
Mr. Bryan Jacobs Chief Financial Officer
Mr. Emilio Presti Director of Sales & Marketing
Dr. Hamed Ghanei Chief Business Officer

Exchange: F

Country: DE : Germany

Currency: Euro (€)

Forward PE: 12.5786
Trailing PE: 17.9661
Price-to-Book MRQ: 2.9044
Price-to-Sales TTM: 10.2951
IPO Date:
Fiscal Year End: December
Full Time Employees: 0
Back to stocks